Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Relay Therapeutics, Inc. - Common Stock (NQ:RLAY)

8.365 -0.095 (-1.12%)
Streaming Delayed Price Updated: 9:47 AM EST, Jan 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Relay Therapeutics, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards
Issued on behalf of Oncolytics Biotech Inc. 
From Equity Insider
Via GlobeNewswire
News headline image
Relay Therapeutics Announces Efficacy Subset Analysis of Zovegalisib (RLY-2608) + Fulvestrant in Breast Cancer Patients Pre-Treated with SERD or with ESR1 Mutations at SABCS 2025
From Relay Therapeutics, Inc.
Via GlobeNewswire
News headline image
Relay Therapeutics Reports Third Quarter 2025 Financial Results and Corporate Updates
From Relay Therapeutics, Inc.
Via GlobeNewswire
News headline image
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in November
From Relay Therapeutics, Inc.
Via GlobeNewswire
News headline image
Relay Therapeutics to Announce Third Quarter 2025 Financial Results and Corporate Highlights on November 6, 2025
From Relay Therapeutics, Inc.
Via GlobeNewswire
News headline image
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September
From Relay Therapeutics, Inc.
Via GlobeNewswire
News headline image
Relay Therapeutics Reports Second Quarter 2025 Financial Results and Corporate Updates
From Relay Therapeutics, Inc.
Via GlobeNewswire
News headline image
Relay Therapeutics to Announce Second Quarter 2025 Financial Results and Corporate Highlights on August 7, 2025
From Relay Therapeutics, Inc.
Via GlobeNewswire
News headline image
Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors
From Relay Therapeutics, Inc.
Via GlobeNewswire
News headline image
Relay Therapeutics Announces Updated Data for RLY-2608 + Fulvestrant Further Demonstrating Clinically Meaningful Progression Free Survival at ASCO 2025
From Relay Therapeutics, Inc.
Via GlobeNewswire
News headline image
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June
From Relay Therapeutics, Inc.
Via GlobeNewswire
News headline image
Relay Therapeutics Reports First Quarter 2025 Financial Results and Corporate Updates
From Relay Therapeutics, Inc.
Via GlobeNewswire
News headline image
Relay Therapeutics to Announce First Quarter 2025 Financial Results and Corporate Highlights on May 5, 2025
From Relay Therapeutics, Inc.
Via GlobeNewswire
News headline image
Relay Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates
From Relay Therapeutics, Inc.
Via GlobeNewswire
News headline image
Relay Therapeutics to Participate in Two Upcoming Investor Conferences
From Relay Therapeutics, Inc.
Via GlobeNewswire
News headline image
Relay Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights on February 26, 2025
From Relay Therapeutics, Inc.
Via GlobeNewswire
News headline image
Relay Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
From Relay Therapeutics, Inc.
Via GlobeNewswire
News headline image
Relay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival
From Relay Therapeutics, Inc.
Via GlobeNewswire
News headline image
Relay Therapeutics to Present Updated Clinical Data on RLY-2608 in HR+/HER2- Breast Cancer at 2024 San Antonio Breast Cancer Symposium
Company to host conference call on Wednesday, December 11, 2024 at 7am ET 
From Relay Therapeutics, Inc.
Via GlobeNewswire
News headline image
Relay Therapeutics and Elevar Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors
From Relay Therapeutics, Inc.
Via GlobeNewswire
News headline image
Relay Therapeutics to Participate in Upcoming Investor Conferences
From Relay Therapeutics, Inc.
Via GlobeNewswire
News headline image
Relay Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Highlights
From Relay Therapeutics, Inc.
Via GlobeNewswire
News headline image
Relay Therapeutics to Announce Third Quarter 2024 Financial Results and Corporate Highlights on November 6, 2024
From Relay Therapeutics, Inc.
Via GlobeNewswire
News headline image
Relay Therapeutics Announces Pricing of Public Offering of Common Stock
From Relay Therapeutics, Inc.
Via GlobeNewswire
News headline image
Relay Therapeutics Announces Proposed Public Offering of Common Stock
From Relay Therapeutics, Inc.
Via GlobeNewswire
News headline image
Relay Therapeutics Announces Positive Interim Data for RLY-2608 Demonstrating Clinically Meaningful Progression Free Survival
From Relay Therapeutics, Inc.
Via GlobeNewswire
News headline image
Relay Therapeutics Announces Webcast to Report RLY-2608 Data on September 9, 2024
From Relay Therapeutics, Inc.
Via GlobeNewswire
News headline image
Relay Therapeutics Reports Second Quarter 2024 Financial Results and Corporate Highlights
From Relay Therapeutics, Inc.
Via GlobeNewswire
News headline image
Relay Therapeutics to Announce Second Quarter 2024 Financial Results and Corporate Highlights on August 6, 2024
From Relay Therapeutics, Inc.
Via GlobeNewswire
News headline image
Relay Therapeutics Discloses Three New Programs at New Program & Platform Event
From Relay Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.